Study on one-pot four-component synthesis of 9-aryl-hexahydro-acridine-1,8- diones using SiO2-I as a new heterogeneous catalyst and their anticancer activity by Ramesh, K.B. & Pasha, M.A.
Bioorganic & Medicinal Chemistry Letters 24 (2014) 3907–3913Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry Letters
journal homepage: www.elsevier .com/ locate/bmclStudy on one-pot four-component synthesis of 9-aryl-hexahydro-
acridine-1,8-diones using SiO2–I as a new heterogeneous catalyst and
their anticancer activityhttp://dx.doi.org/10.1016/j.bmcl.2014.06.047
0960-894X/ 2014 Elsevier Ltd. All rights reserved.
⇑ Corresponding author. Tel.: +91 80 22961337; fax: +91 80 22961331.
E-mail address: m_af_pasha@ymail.com (M.A. Pasha).K. B. Ramesh, M. A. Pasha ⇑
Department of Studies in Chemistry, Central College Campus, Palace Road, Bangalore University, Bengaluru 560001, Indiaa r t i c l e i n f o
Article history:
Received 24 January 2014
Revised 3 June 2014
Accepted 17 June 2014
Available online 25 June 2014
Keywords:
9-Aryl-hexahydro-acridine-1,8-diones
Aromatic aldehydes
Dimedone
Ammonium acetate
Silica iodide
Anticancer activitya b s t r a c t
A simple, efﬁcient and cost-effective method for the synthesis of 9-aryl-hexahydro-acridine-1,8-diones
by a one-pot four-component cyclocondensation of dimedone, aromatic aldehydes and ammonium ace-
tate as a nitrogen source in the presence of a new heterogeneous catalyst silica iodide (SiO2–I) in EtOH at
80 C is described. SiO2–I was subjected to SEM–EDX and found to have iodo group bound to the catalyst.
Some of the prepared acridine-diones were found to exhibit promising anti-cancer activity against HepG2
and MCF-7 cell lines.
 2014 Elsevier Ltd. All rights reserved.Multicomponent reactions (MCRs) have emerged as efﬁcient
and powerful strategies in the modern synthetic organic chemistry
because synthesis of complex organic molecules from simple and
readily available substrates can be achieved in a very fast and efﬁ-
cient manner without the isolation of any intermediates.1 MCRs
contribute to the requirements of an environment friendly process
by reducing the number of synthetic steps, energy consumption
and waste production.2 Therefore, developing new MCRs and
improvement of known MCRs are popular areas of research in
the current synthetic organic chemistry. MCRs play a major role
in several biological processes and proliferation of cancer cells.3
Cancer is one of the lethal diseases which can lead to human death.
In most of the cases multi-drug resistance generally leads to the
failure of chemotherapy; and most of the drugs used for the treat-
ment of cancer are cytotoxic drugs which lack the site speciﬁc
activity to cancer cells and lead to damage of the healthy cells.
Many research groups have shown anticancer activity of different
acridine analogs (Fig. 1), including compounds 1 and 2 on cancer
cells.4
Derivatives of acridine 3 and 4 (Fig. 2) showed good cytotoxic
activity against human leukaemia cells.5
Derivative of acridine such as 5 (Fig. 3) was found to be the
most potent drug towards the metastatic breast cancer cells.6Acridines are an important class of organic compounds which
ﬁnd use as dyes, ﬂuorescent materials for visualization of biomol-
ecules, and in laser technology due to their useful spectroscopic
properties.7 Acridines have also received signiﬁcant attention from
many pharmaceutical and organic chemists, essentially because of
the broad spectrum of their biological and pharmaceutical proper-
ties, such as: antiviral,8 antibacterial,9 anti-nociceptive activities,10
as well as efﬁciency in photodynamic therapy11 and because of the
anti-inﬂammatory activity.12 There are a few reports in the litera-
ture on the three-component Hantzsch-type condensation of
aromatic aldehydes, anilines and dimedone via the traditional
heating in organic solvents13,14 under microwave irradiation15
and in ionic liquids16,17 leading to acridines. The main drawback
of these methods is the inability to synthesize 9-aryl-hexahydro-
acridine-1,8-diones, therefore, the development of simple,
efﬁcient, high-yielding and environment friendly methods and
use of simple, readily available, recyclable, new heterogeneous
catalysts for the preparation of acridines under mild conditions is
in demand.
In recent years, the heterogeneous catalysis has developed con-
siderable interest in the various disciplines of science including
organic synthesis due to the prime advantage that, in most of the
cases the heterogeneous catalysts can be recovered with only
minor change in activity and selectivity so that they can be used
in continuous ﬂow reactions.18 Heterogeneous catalysts have many
advantages over their homogeneous counterparts. Generally
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cause low corrosion, and show environmental acceptability. Also,
the products can be easily separated from the reaction mixture
and the catalyst is recoverable, and we have prepared a new
heterogeneous catalyst-SiO2–I form silica through its chloride
and used successfully in the synthesis of acridines by a one-pot
four-component reaction. Due to our interest in the synthesis of
heterocyclic compounds,19–22 and in continuation of our previous
work on the application of reusable catalysts in organic reactions,23
we, herein, report a new and an efﬁcient synthesis of some novel
and known 9-aryl-hexahydro-acridine-1,8-diones from two moles
of dimedone, one mole of benzaldehyde and one mole of
ammonium acetate as shown in the Scheme 1.
We have found that, the prepared acridine analogues show
promising effect on cancer cell proliferation.
Materials and methods: All chemicals were commercially avail-
able and used without further puriﬁcation, except liquid aldehydes
which were distilled before use. All yields refer to isolated products
after puriﬁcation. Products were characterized by the IR, 1HNMR,
13CNMR, Mass spectral and CHN analyses. Melting points were
measured on a Raaga, Indian make melting point apparatus. NMR
spectra were obtained on a 400 MHz and 100 MHz Bruker AMX
instruments in CDCl3 using TMS as a standard. ESI-MS analysis
was carried out using ESI-Q TOF instrument. Silica, silica chloride
and silica Iodide were characterised by SIRION high resolution
Scanning Electron Microscope–Energy Dispersive X-ray spectro-
scopic (SEM–EDX) technique.
Preparation of silica iodide: Silica gel (20 g) was suspended in
CH2Cl2 (50 mL), and SOCl2 (20 mL) was added drop wise with con-
tinuous stirring at 26 C. Evolution of HCl and SO2 occurred instan-
taneously; after stirring for 1 h, the solvent was removed by
distillation; and the residual solvent was removed under reduced
pressure to get a dry solid of silica chloride (26.2 g). The solid
SiO2–Cl was washes with cold water and dried under vacuum.
NaI (3 g) was ﬁrst dissolved in a mixture of EtOH–H2O (8:2,
10 mL), to this silica chloride (6 g) was added, mixed well and
ﬁltered after 15 min, washed with cold water and dried under
vacuum to get SiO2–I (7.5 g).
Detection of the iodide in silica iodide. Qualitative analysis. Test: 1.
To detect the presence of iodide in the catalyst, 0.25 mg of silica
iodide was transferred to a dry test tube; 0.25 mg of sodium metal
was then introduced and heated till the test tube turned red-hot.
After cooling the test tube, water (3 mL) was introduced and ﬁl-
tered to get the sodium fusion extract (SFE). SFE (1.5 mL) was then
acidiﬁed with dil. HNO3 and treated with AgNO3 solution to get a
pale yellow precipitate which was insoluble in aqueous ammonia
to conﬁrm the presence of iodide in the heterogeneous catalyst.24
Test: 2. SFE (1.5 mL) was acidiﬁed with dil. HCl, carbon tetra-
chloride (0.3 mL) was then added and treated with chlorine water
(1 mL) to get a violet globule which conﬁrmed the presence of
iodide in the heterogeneous catalyst.°C
R
N
H
O O
/EtOH
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xahydro-acridine-1,8-diones.
Figure 4. SEM–EDX of (a) silica, (b) silica chloride and (c) silica iodide.
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Scheme 2. A plausible mechanism for the formation of acridines.
Table 1
Effect of solvent on the synthesis of 9-phenyl-hexahydro-acridine-1,8-diones (4a)
Entry Solvent Temperature (C) Time (h) Yielda (%)
1 CH3CN 83 5 45
2 H2O 98 5 55
3 MeOH 65 4 50
4 EtOH 80 3 60
5 CH2Cl2 40 6 Traceb
6 THF 68 5 55
7 Solvent-free 70 6 40
a Isolated yield.
b TLC.
Table 2
Inﬂuence of various catalysts on the synthesis of phenyl-hexahydro-acridine-1,8-
diones (4a)
Entry Catalysta Time (h) Yieldc (%)
1 AmberliteIR120H 13 20
2 ZnCl2b 11 30
3 CeCl3b 12 35
4 K2CO3b 10 45
5 NaIb 12 —
6 SiO2a 10 35
7 SiO2–Cla 5 70
8 SiO2–Ia 2.5 90
a 0.1 g.
b 10 mol %.
c Isolated yield.
Table 3
Optimization of the amount of SiO2–I
Entry SiO2–I (g) Amount of NH4OAc (mmol) Time (h) Yielda (%)
1 0 2 8 40
2 0.01 2 15 50
3 0.05 2 10 55
4 0.06 2 2 60
5 0.08 2 2.5 70
6 0.10 2 2.5 90
7 0.15 2 2.5 90
8 0.20 2 2.5 90
9 0.25 2 2.5 90
a Isolated yield.
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in present in silica iodide.
Quantitative analysis. Test: 1. SiO2–I (1 g) was then taken in a
250 mL conical ﬂask and titrated against 0.04 N Na2S2O3 and found
to have 0.33 milli-equivalent of iodide in it by the method devel-
oped by McDanlel.25,26
Test: 2 (SEM–EDX analysis). The SEM micrographs of silica and
silica based catalysts viz., chloride and iodide are shown in Figure 4.
SEM micrographs showed both chloride and iodide to have similar
texture and that the iodide and chloride in these materials is uni-
formly dispersed on silica surface and both can be used as hetero-
geneous catalysts Figure 4(b and c). Also, we have determined the
composition of the silica, silica chloride and silica iodide by EDX
studies. The EDX plots are shown in Figure 4 (a, b and c) along with
the SEM micrographs.
Table 4
SiO2–I catalyzed synthesis of acridines 4a–k in ethanol at 80 C
Entry Aldehydes Producta Time (h) Yieldb (%) Mp (C)
Found Reported
1 C6H5CHO 4a 2.5 90 249–251 258–26028
2 3-CNC6H4CHO 4b 2.8 87 215–218 —
3 4-MeOC6H4CHO 4c 2.5 89 271–272 270–27229
4 4-ClC6H4CHO 4d 1.5 82 298–301 299–30130
5 4-NO2C6H4CHO 4e 2 86 284–287 286–28830
6 3-Br,4-MeOC6H3CHO 4f 2 89 238–241 —
7 3-C2H5OC6H4CHO 4g 2.6 79 210–213 —
8 5-F,2-HOC6H3CHO 4h 2 85 210–215 —
9 2-HOC6H4CHO 4i 2.5 74 223–225 —
10 2,4-(CH3O)2C6H3CHO 4j 2.3 83 291–296 —
11 4-(CH3)2NC6H4CHO 4k 2 80 281–283 280–28231
a Isolated yield. All the synthesized products were characterized from their spectroscopic analytical data (IR, NMR, CHN, ESI-MS), except 4a which was compared on TLC
with the authentic sample.
b Isolated yield.
 Novel compounds.
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acridines involves the activation of aldehyde followed the attack
of enol form of the dimedone to give the intermediate I. The inter-
mediate I may react with another molecule of dimedone to give II.
Attach of ammonia formed from ammonium acetate gives III, and
III may cyclise to give the acridine derivative IV which after the
elimination of a molecule of water may give V. In the last step V
may lose both the catalyst and another molecule of water to give
acridines as shown in the Scheme 2.
We studied the effect of several solvents like acetonitrile, water,
methanol, dichloromethane, and tetrahydrofuran on the reaction
of twomoles of dimedone, one mole of benzaldehyde and one mole
of ammonium acetate. The reaction in tetrahydrofuran, water, ace-
tonitrile afforded the product but yields were poor. The best results
in terms of yield and reaction time were obtained with ethanol as a
solvent (Table 1, entry 4). We, then decided to investigate the efﬁ-
cacy of SiO2–I for the synthesis of 4a under solvent-free condition
also, but, ended up getting the product in only 40% yield (entry 7).
We studied the effect of different catalysts such as
AmberliteIR120H, ZnCl2, CeCl3, K2CO3, NaI, SiO2, SiO2-Cl and
SiO2-I also on the preparation of 4a, and found that, SiO2-I is best
in terms of yield and duration of the reaction (Table 2, entry 8).
Further studies were carried out to optimize the amount of cat-
alyst by using different amounts of SiO2–I (0.06, 0.08, 0.10, 0.15,
0.20 and 0.25 g) and the results of this study are presented in the
Table 3. From this Table, it is clear that, 0.1 g of SiO2–I afforded
the product in 90% isolated yield (Table 3, entry 6). Increasing
the amount of catalyst did not improve the yield (entries 7–9).0 
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Figure 5. Reusability of silica iodide in the synthesis of 4a.We then started our work by examining the possibility of an
one-pot four-component reaction involving two molecules of
dimedone (1, Scheme 1), one molecule of benzaldehyde (2) and a
molecule of ammonium acetate (3) to get 9-phenyl-hexahydro-
acridine-1,8-dione (4a) in ethanol as a solvent in the presence of
SiO2–I.
A mixture of 1, 2, and 3 (Scheme 1) in 1.5 mL ethanol was stir-
red in the presence of SiO2–I for 2–3 h at 80 C to get 4a in 90%
yield.27 Encouraged by this result, the reaction of various substi-
tuted arylaldehydes was taken up and the results of this study
are presented in the Table 4. The data presented in Table 4 indi-
cates that SiO2–I serves as an excellent catalyst for the synthesis
different substituted acridines in excellent yield in short reaction
duration.
Study on reusability of SiO2–I catalyst:With an effort to make the
present reaction much greener, the recovery and reusability of the
catalyst was studied. After the completion of the reaction, the solid
thus separated was ﬁltered along with the catalyst. The residue
containing the catalyst was washed with ether to get the solid
SiO2–I which was then dried at 100 C for 2 h and reused. The
results of the study of the reusability of the catalyst are presented
in the form of a graph in Figure 5. From Figure 5, it is clear that
SiO2–I can be used successively for at least four runs after the ﬁrst
fresh run, after which the yield of the product dropped from 90% in
the ﬁrst fresh run to 67% in the ﬁfth run. The yield of 4a was found
to be 90%, 88%, 81%, 76% and 67%, respectively, for 1–5 cycles, the
marginal decrease of yield in the ﬁrst ﬁve cycles may be due to loss
of the catalyst during the recovery.
Cell culture: HepG2 (Hepatocellular carcinoma cells) and MCF-7
(Human breast adenocarcinoma cells) cell lines were procured
from National Centre for Cell Sciences (NCCS), Pune, India. The cells
were cultured in minimum essential medium (MEM) growth med-
ium supplemented with 10% heat inactivated Fetal bovine serum
(FBS), penicillin (100 IU/mL), streptomycin (100 lg/mL) and
amphotericin-B (5 lg/mL) in a humidiﬁed atmosphere of 5% CO2
at 37 C until conﬂuent. The cells were trypsinized with TPVG solu-
tion (0.2% trypsin, 0.02% EDTA, 0.05% glucose in PBS). The cultures
were grown in 25 cm2 ﬂat bottles and the studies were carried out
in 96 wells plates.
MTT assay32: Cells were plated in 96 wells plate (1  104 cells/
well) and cultured for 24 h at 37 C in 5% CO2 atmosphere to allow
cell adhesion. After 24 h, when partial monolayer was formed, cells
were treated with different concentration of standard drug (Doxo-
rubicin) and sample compounds for 48 h. Microscopic examination
was carried out and observations recorded every 24 h. After the
treatment, the solutions in the wells were discarded and 50 lL of
Table 5
In vitro anticancer activity of acridine derivatives on HepG2 and MCF-7 human cancer
cell lines
Drug/
formulation
IC50value (lg/mL) on HepG2
cells (Hepatocellular carcinoma
cells)
IC50 value (lg/mL)
on MCF-7 cells (Human
breast adenocarcinoma
cells)
Doxorubicin 1.21 ± 0.05 1.09 ± 0.03
4b 1.4 ± 0.11 4.7 ± 0.09
4c 8.2 ± 0.32 9.6 ± 0.22
4f 2.2 ± 0.09 5.3 ± 0.16
4g 4.8 ± 0.12 4.5 ± 0.10
4h 8.6 ± 0.31 6.2 ± 0.14
4i 2.6 ± 0.11 5.9 ± 0.15
4j 1.6 ± 0.14 5.0 ± 0.18
 Active.
3912 K. B. Ramesh, M. A. Pasha / Bioorg. Med. Chem. Lett. 24 (2014) 3907–3913freshly prepared MTT (2 mg/mL, prepared in PBS) was added to
each well. The plates were shaken gently and incubated for 3 h
at 37 C in 5% CO2 atmosphere. The supernatant was removed
and the formazan crystals formed in the cells were solubilised by
addition of 50 lL of iso-propanol. Finally, the absorbance was
recorded using a Micro-plate reader (Bio-Tek, ELX-800 MS) at a
wavelength of 540 nm.
%growth inhibition¼ control absorbance test absorbance
control absorbance
100
The percentage growth was calculated using the standard for-
mula and IC50 values are shown in the Table 5.
The data presented in the Table 5 shows the IC50 values obtain
by the treatment of the prepared acridines with the standard drug
(Doxorubicin) on HepG-2 and MCF-7 cells. It is clear from this
Table that, compounds 4b, 4f, 4i and 4j exhibit very good activity
towards HepG2 cell lines and 4b, 4f, 4g and 4j showed compara-
tively better activity towards MCF-7 cell lines.
In conclusion a reliable, practical procedure and an alternative
method for the synthesis of 9-aryl-hexahydro-acridine-1,8-diones
has been developed. The method involves the use of silica iodide,
a new heterogeneous catalyst which has made this method cost
effective, as the catalyst can be recycled for at least ﬁve runs with-
out loss of activity and the reaction involves simple workup proce-
dure. The compounds 4b, 4f, 4i and 4j exhibited very good activity
towards HepG2 cell lines and 4b, 4f, 4g and 4j showed compara-
tively better activity towards MCF-7 cell lines which can be a plen-
tiful source of potential anti-cancer drugs deserving further study.
In our opinion this method is superior to all other previously
reported methods33,34 of synthesis of 9-aryl-hexahydro-acridine-
1,8-diones.
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dione(4b):
Colorless solid, mp: 215–218 C; IR (KBr, m cm1): 2240 (C–N), 3340 (N–H),
1710 (C@O); 1H NMR (400 MHz, CDCl3): d 1.10 (s, 6H, 2Me), 1.23 (s, 6H, 2Me),
2.40 (m, 8H, 4CH2), 5.49 (s, 1H, CH), 7.26–7.48 (m, 4H, Ar-H), 11.80 (s, 1H, N–
H); 13C NMR (400 MHz, CDCl3): d 27.9, 29.8, 31.9, 33.1, 46.8, 47.4, 77.1, 77.4,
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Anal. Calcd C24H26N2O2: C, 76.98; H, 7.00; N, 7.48; Found C, 75.34; H, 7.09; N,
8.29.
9-(40-Methoxyphenyl)-3,3,6,6-tetramethyl-2,4,5,7,9,10-hexahydro-acridine-
1,8-dione (4c):
Colorless solid, mp: 271–272 C; IR (KBr, m cm1): 3320 (N–H), 1720 (C@O); 1H
NMR (400 MHz, CDCl3): d 1.09 (s, 6H, 2Me), 1.22 (s, 6H, 2Me), 2.37 (m, 8H,
4CH2), 3.73 (s, 3H, OCH3), 5.48 (s, 1H, CH), 6.79 (dd, 2H, J = 8.0, 4.0 Hz, Ar-H),
6.98 (dd, 2H, J = 8.8, 0.8 Hz, Ar- H), 11.91 (s, 1H, N–H); 13C NMR (400 MHz,
CDCl3): d 27.81, 29.72, 30.11, 31.82, 32.46, 32.64, 41.29, 46.87, 47.51, 51.91,
55.54, 55.64, 113.90, 114.08, 116.23,128.23, 129.75, 130.26, 136.91, 158.02,
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NMR (400 MHz, CDCl3): d 1.09 (s, 6H, 2Me), 1.21 (s, 6H, 2Me), 2.18–2.48 (m,
8H, 4CH2), 5.47(s, 1H, CH), 6.99–7.26 (m, 5H, Ar-H), 11.87 (s, 1H, NH);
ESI-MS: [M+H] 384.3; Anal. Calcd C23H26ClNO2: C, 71.96; H, 6.83; N, 3.65;
Found C, 71.03; H, 7.02; N, 3.09.
9-(40-Nitrophenyl)-3,3,6,6-tetramethyl-2,4,5,7,9,10-hexahydro-acridine-1,8-
dione (4e):
Colorless solid, mp: 284–287 C; IR (KBr, m cm1): 1550 (NO2), 3343 (N–H),
1716 (C@O); 1H NMR (400 MHz, CDCl3): d 1.12 (s, 6H, 2Me), 1.27 (s, 6H, 2Me),
2.31 (m, 8H, 4CH2), 5.54(s,1H,CH), 7.39 (dd, 2H, J = 12.4, 8.0 Hz, Ar-H), 8.00 (dd,
2H, J = 11.2, 11.2 Hz, Ar-H), 11.86 (s, 1H, N–H);
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Anal. Calcd C23H26N2O4: C, 70.03; H, 6.64; N, 7.10; Found C, 69.31; H, 6.09; N,
6.29.
9-(30-Bromo-40-methoxyphenyl)-3,3,6,6-tetramethyl-2,4,5,7,9,10-hexahydro-
acridine-1,8-dione (4f):
Colorless solid, mp: 238–241 C; IR (KBr, m cm1): 3369 (N–H), 1728 (C@O); 1H
NMR (400 MHz, CDCl3): d 0.93 (s, 6H, 2Me), 1.10 (s, 6H, 2Me), 2.09–2.52 (m,
8H, 4CH2), 3.79 (s, 3H, OMe), 4.78 (1H,CH), 6.71 (d, 1H, J = 8.8 Hz), 7.03 (s, 1H,
Ar-H), 7.27 (d, 1H, J = 2.4 Hz), 10.28 (s, 1H, NH);
ESI-MS: [M+H] 458.3;
Anal. Calcd C24H28BrNO3: C, 62.88; H, 6.16; N, 3.06; Found C, 62.46; H, 6.19; N,
3.0.
9-(30-Ethoxyphenyl)-3,3,6,6-tetramethyl-2,4,5,7,9,10-hexahydro-acridine-1,8-
dione (4g):
Colorless solid, mp: 210–213 C; IR (KBr, m cm1): 3310 (N–H), 1724 (C@O); 1H
NMR (400 MHz, CDCl3), d 1.05 (s, 6H, 2Me),1.16 (s, 6H, 2Me),1.32 (t, 3H,
J = 6.8 Hz) 1.95–2.50 (m, 8H, 4CH2), 3.31(s, 1H, NH), 4.01–4.03 (q, 2H,
J = 8.8 Hz), 4.84 (s, 1H, CH), 6.81(s, 1H, Ar-H), 6.83 (d, 1H, J = 8.4 Hz), 6.96(d,
1H, J = 7.2 Hz), 7.15 (t, 1H, J = 6.8 Hz);
ESI-MS: [M+H] 394.2;
Anal. Calcd C25H31NO3: C, 76.30; H, 7.94; N, 3.56; Found C, 75.28; H, 7.09; N,
3.29.
9-(50-Fluoro-20-hydroxyphenyl)-3,3,6,6-tetramethyl-2,4,5,7,9,10-hexahydro-
acridine-1,8-dione (4h):
Colorless solid, mp: 210–215 C; IR (KBr, m cm1): 3400 (O–H), 3390 (N–H),
1725 (C@O); 1H NMR (400 MHz, CDCl3): d 0.99 (s, 6H, 2Me),1.12 (s, 6H, 2Me),
1.97–2.49 (m, 8H, 4CH2), 2.55(s, 1H, OH), 4.62 (s, 1H, CH), 6.68 (d, 1H,
J = 3.2 Hz, Ar-H), 6.81(d, 1H, J = 3.2 Hz, Ar-H), 6.96 (s, 1H, Ar-H) 10.48 (s, 1H, N–
H); 13C NMR (400 MHz, CDCl3): d 27.6, 28.18, 29.59, 31.40, 32.75, 41.98, 50.35,
111.43, 116.20, 118.75, 124.67, 125.04, 128.00, 128.42, 151.44, 169.64; ESI-
MS: [M+H] 384.3;
Anal. Calcd C23H26FNO3: C, 72.04; H, 6.83; N, 3.65; Found C, 71.62; H, 6.05; N,
3.21.
9-(20-Hydroxyphenyl)-3,3,6,6-tetramethyl-2,4,5,7,9,10-hexahydro-acridine-
1,8-dione (4i)
Colorless solid, mp: 223–225 C; IR (KBr, m cm1): 3412 (O–H), 3356 (N–H),1789 (C@O); 1H NMR (400 MHz, CDCl3): d 0.99 (s, 6H, 2Me), 1.02 (s, 6H, 2Me),
2.33–2.58 (m, 8H, 4CH2) 2.62 (s, 1H, OH), 4.68 (s, 1H, CH), 6.99–7.18 (m, 4H, Ar-
H), 11.0 (s, 1H, N–H);
ESI-MS: [M+H] 366.1;
Anal. Calcd C23H27NO3: C, 75.59; H, 7.45; N, 3.83; Found C, 75.43; H, 7.07; N,
3.20.
9-(20 ,40-Dimethoxyphenyl)-3,3,6,6-tetramethyl-2,4,5,7,9,10-hexahydro-
acridine-1,8-dione (4j):
Colorless solid, mp: 291–296 C; IR (KBr, m cm1): 3330 (N–H), 1728 (C@O); 1H
NMR (400 MHz, CDCl3) d 0.92 (s, 6H, 2Me), 1.09 (s, 6H, 2Me), 1.95–2.50 (m, 8H,
4CH2), 3.74 (s, 3H,OMe), 3.79 (s, 3H,OMe), 3.95 (s, 1H, NH), 4.73 (s, 1H, CH),
6.34 (d, 1H, J = 2.8 Hz, Ar-H), 6.45 (s, 1H, Ar-H), 6.85 (d, 1H, J = 8.4 Hz);
ESI-MS: [M+H] 410.2;
Anal. Calcd C25H31NO4: C, 73.32; H, 7.63; N, 3.42; Found C, 72.04; H, 7.00; N,
3.19.
9-(40-N,N-Dimethylaminophenyl)-3,3,6,6-tetramethyl-2,4,5,7,9,10-hexahydro-
acridine-1,8-dione (4k):
Colorless solid, mp: 281–283 C; IR (KBr, m cm1): 3387 (N–H), 1756 (C@O); 1H
NMR (400 MHz, CDCl3): d 1.08 (s, 6H, 2Me), 1.22 (s, 6H, 2Me), 2.31–2.44 (m,
8H, 4CH2), 3.80 [s, 6H, N(CH3)2], 5.54 (s, 1H, CH), 6.54–7.44 (m, 4H, Ar-H), 11.9
(s, 1H, N–H);
ESI-MS: [M+H] 393.2;
Anal. Calcd C25H32N2O2: C, 76.49; H, 8.22; N, 7.14; Found C, 75.72; H, 7.04; N,
6.29.
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